Clever Culture Systems (CC5) H2 2024 earnings summary

Executive summary

• Strategic pivot to pharmaceutical environmental monitoring market, leveraging APAS® technology and AI for automated culture plate reading.

• Partnership with AstraZeneca led to successful product development, validation, and initial sales, establishing a foundation for broader market adoption.

• Commercial focus shifted from clinical to pharmaceutical sector, targeting large multinational manufacturers and CDMOs.

• Financial restructuring included a $4.5 million capital raise and loan renegotiation, improving liquidity and supporting growth.

Financial highlights

• Net loss after tax for FY24 was $3.74 million, a significant improvement from FY23's $22.52 million loss (which included $13.41 million impairment and $5.69 million deferred tax write-off).

• Revenue for FY24 was $1.71 million, down from $2.27 million in FY23; includes $0.54 million from APAS® Independence sales and $0.72 million consulting income.

• Cash balance at 30 June 2024 was $2.4 million, with expected near-term inflows of over $1.7 million.

• Net assets increased to $2.42 million from a negative $0.1 million in FY23.

• Cash reserves increased by $0.33 million during the year.

Outlook and guidance

• FY25 focus on establishing APAS® Independence as the standard for pharmaceutical environmental monitoring.

• Eight APAS® instruments to be delivered and implemented in the first half of FY25; five to AstraZeneca, others to CDMO and pharma customers.

• Continued expansion of commercial activities, targeting large pharma and technology innovators.

• Ongoing support for clinical market sales through distribution partner, but primary growth expected from pharmaceutical sector.